We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DENTSPLY SIRONA Inc. (XRAY - Free Report) is one of the leading worldwide manufacturers’ dental consumables, dental laboratory products, dental specialty products and consumable medical device products. Post DENTSPLY-SIRONA merger, the business has been organized into two reporting segments: Dental & Healthcare Consumables and Technologies.
Currently, this York, PA- based company carries a Zacks Rank #3 (Hold) but that could change following its third quarter 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:
Earnings: DENTSPLY reported adjusted earnings of 70 cents per share, which came above the Zacks Consensus Estimate by 4 cents and was higher than earnings of 66 cents in the year-ago quarter.
Revenues: DENTSPLY’s net sales increased to $1,009.2 million from $954.0 million in the year-ago period. This also came above the Zacks Consensus Estimate of $978.0 million. Net sales, excluding precious metals, increased 4.3% on a constant currency basis and internal growth was 2.4% as compared to the third quarter of 2016.
Narrowed Guidance: The company narrowed its adjusted EPS guidance for 2017 to the range of $2.65 to $2.70 per share. Earlier, the company projected adjusted EPS in a range of $2.65 to $2.75.
Check back later for our full write up on this DENTSPLY earnings report later!
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
DENTSPLY (XRAY) Q3 Earnings Beat Estimates, Sales Rise Y/Y
DENTSPLY SIRONA Inc. (XRAY - Free Report) is one of the leading worldwide manufacturers’ dental consumables, dental laboratory products, dental specialty products and consumable medical device products. Post DENTSPLY-SIRONA merger, the business has been organized into two reporting segments: Dental & Healthcare Consumables and Technologies.
Currently, this York, PA- based company carries a Zacks Rank #3 (Hold) but that could change following its third quarter 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:
Earnings: DENTSPLY reported adjusted earnings of 70 cents per share, which came above the Zacks Consensus Estimate by 4 cents and was higher than earnings of 66 cents in the year-ago quarter.
Revenues: DENTSPLY’s net sales increased to $1,009.2 million from $954.0 million in the year-ago period. This also came above the Zacks Consensus Estimate of $978.0 million. Net sales, excluding precious metals, increased 4.3% on a constant currency basis and internal growth was 2.4% as compared to the third quarter of 2016.
DENTSPLY SIRONA Inc. Price and EPS Surprise
DENTSPLY SIRONA Inc. Price and EPS Surprise | DENTSPLY SIRONA Inc. Quote
Narrowed Guidance: The company narrowed its adjusted EPS guidance for 2017 to the range of $2.65 to $2.70 per share. Earlier, the company projected adjusted EPS in a range of $2.65 to $2.75.
Check back later for our full write up on this DENTSPLY earnings report later!
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>